NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Year
01 avr. 2024 07h50 HE
|
NEXGEL, INC.
LANGHORNE, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare...
NEXGEL Reschedules Fourth Quarter and Full Year 2023 Financial Results Conference Call to Monday, April 1st at 8:30 a.m. ET Due to Holiday
27 mars 2024 09h00 HE
|
NEXGEL, INC.
LANGHORNE, Pa., March 27, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including...
NEXGEL to Report Fourth Quarter and Full Year 2023 Financial Results on March 28th
21 mars 2024 09h00 HE
|
NEXGEL, INC.
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., March 21, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading...
NEXGEL to Present at the iAccess Alpha Best Ideas Spring Virtual Conference on March 12th
04 mars 2024 08h30 HE
|
NEXGEL, INC.
LANGHORNE, Pa., March 04, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including...
NEXGEL Announces $975,000 Registered Direct Offering Led by Insiders
21 févr. 2024 16h05 HE
|
NEXGEL, INC.
LANGHORNE, Pa., Feb. 21, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle,...
NEXGEL to Present at The Microcap Conference, January 30th through February 1st
18 janv. 2024 09h00 HE
|
NEXGEL, INC.
LANGHORNE, Pa., Jan. 18, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare...
NEXGEL Subsidiary, CG Converting and Packaging, Begins 12,000 Square Foot Expansion of Texas Facility to Support the Expected Growth in Product Demand in 2024
09 janv. 2024 08h30 HE
|
NEXGEL, INC.
LANGHORNE, Pa., Jan. 09, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle,...
NEXGEL Announces Partnership with STADA to Distribute and Commercialize Consumer Health OTC Products in North America
11 déc. 2023 08h00 HE
|
NEXGEL, INC.
LANGHORNE, Pa., Dec. 11, 2023 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle,...
NEXGEL Acquires Kenkoderm Psoriasis Skincare Line
05 déc. 2023 08h00 HE
|
NEXGEL, INC.
Acquisition expands NEXGEL’s health and wellness consumer product portfolio Synergies support optimization of marketing and supply chain operations to drive revenue growth and margins Kenkoderm for...
NEXGEL Reports Record Third Quarter 2023 Revenue of $1.2 Million, an Increase of 115% Year-Over-Year
13 nov. 2023 16h05 HE
|
NEXGEL, INC.
Gross profit margin improved sequentially to 28.2% in Q3 as compared to 15.0% in Q2 LANGHORNE, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a...